Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

3 april 2012 uppdaterad av: University of California, San Francisco

A Phase I Study, With Expanded Cohort, of Biweekly Fixed-dose Rate Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic and Biliary Carcinomas

The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and capecitabine are two chemotherapy drugs used to treat pancreatic and biliary cancer. These two drugs used together are considered an acceptable standard of care for pancreatic and biliary cancers. However, in this study the dose and dosing schedule will be changed, in the hopes that the drugs will have more effect with fewer side effects than when given in the standard way.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

45

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • San Francisco, California, Förenta staterna, 94115
        • UCSF Helen Diller Family Comprehensive Cancer Center
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84112
        • Huntsman Cancer Center, University of Utah

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Histologically-confirmed pancreatic adenocarcinoma or biliary tract carcinoma (cholangiocarcinoma or gallbladder cancer)
  • Disease must not be amenable to surgical resection. Patients with either locally advanced or metastatic disease are eligible
  • No prior systemic therapy for their diagnosis
  • ECOG performance score of 0-1
  • Evidence of either or both of the following:

    1. RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter ≥ 20mm using conventional techniques or ≥10 mm with spiral CT scan)
    2. An elevated serum CA19-9 at baseline ( ≥ 2X ULN)
  • Female patients must be either surgically sterile or postmenopausal, or if of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment and agree to use effective barrier contraception during the period of therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator.
  • Adequate bone marrow function:

    1. ANC ≥ 1500/uL
    2. platelet count ≥ 100,000/uL
    3. hemoglobin ≥ 9.0 g/dL
  • Adequate hepatic function:

    1. Total bilirubin ≤ 1.5 X ULN
    2. AST (SGOT) ≤ 2.5 X ULN
    3. ALT (SGPT) ≤ 2.5 X ULN
  • Adequate renal function as determined by either:

    1. Calculated or measured creatinine clearance ≥ 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used)
    2. Serum creatinine ≤ 1.5 X ULN
  • Ability to swallow oral medications
  • Ability to understand the nature of this study protocol and give written informed consent
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Any prior systemic or investigational therapy for metastatic or locally advanced pancreatic cancer or biliary cancer. Systemic therapy administered alone or in combination with radiation in the adjuvant setting is permissible as long as it was completed > 6 months prior to the time of study enrollment.
  • Inability to comply with study and/or follow-up procedures.
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.
  • Presence of central nervous system or brain metastases.
  • Pregnancy (positive pregnancy test) or lactation.
  • Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years.
  • Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
  • Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
  • Known, existing uncontrolled coagulopathy.
  • Major surgery within 4 weeks of the start of study treatment, without complete recovery.
  • Concurrent/pre-existing use of coumadin.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Gem/Cape
1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
Andra namn:
  • gemzar
starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
Andra namn:
  • xeloda

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
To establish the maximum tolerated dose of fixed-dose rate gemcitabine plus capecitabine given by biweekly administration in patients with advanced pancreatic and biliary tract malignancies.
Tidsram: 2 years
2 years

Sekundära resultatmått

Resultatmått
Tidsram
Total överlevnad
Tidsram: 2 år
2 år
Objective response rate (ORR) and disease control rate (DCR) in patients with measurable disease at baseline
Tidsram: 2 years
2 years
Biomarker (CA19-9) response rate (decline by ≥ 50%) in patients with elevated CA19-9 (≥ 2x ULN) at baseline.
Tidsram: 2 years
2 years
Time to tumor progression (TTP)
Tidsram: 2 years
2 years
Frequency, type, and grade of adverse events using this combination in this patient population
Tidsram: 2 years
2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Andrew Ko, MD, University of California, San Francisco

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 februari 2008

Primärt slutförande (Faktisk)

1 december 2010

Avslutad studie (Faktisk)

1 december 2010

Studieregistreringsdatum

Först inskickad

14 februari 2008

Först inskickad som uppfyllde QC-kriterierna

28 februari 2008

Första postat (Uppskatta)

29 februari 2008

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

4 april 2012

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 april 2012

Senast verifierad

1 april 2012

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera